Quantcast
Last updated on April 17, 2014 at 12:30 EDT

Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates

April 24, 2013

LAUSANNE, Switzerland, April 24, 2013 /PRNewswire/ –

Oncotest GmbH and Debiopharm Group(TM) (Debiopharm) a Swiss-based global
biopharmaceutical group, are pleased to announce the successful completion of the first
biomarker projects at Oncotest. In a recent study, pharmacological data was generated with
Debiopharm’s investigational compound in Oncotest’s 3D assay system for patient-derived
xenografts and correlated with the extensive Oncotest’s genomic and transcriptomic data.
The collaboration resulted in the identification of several predictive biomarkers
candidates including a gene signature.

“We are enthusiastic to work with Debiopharm on these projects and are looking forward
to continue and expand our collaboration. I am convinced that the concept of deriving
predictive biomarkers for new drugs already in a preclinical setting will make an impact.
Ultimately, it has a significant potential to lower the attrition rates in clinical
trials. Today, with our new biomarker department and the characterization data available
for our tumor models, Oncotest is ideally positioned in this area.” said Prof. Heiner
Fiebig, Founder and CEO of Oncotest.

Dr. Hiroaki Tanaka, Personalized Medicine Director at Debiopharm added: “Reliable
preclinical models are key success factors in drug development. We believe that
technologies based on the direct use of patient tumors have a game-changer potential in
translational research in oncology. We are happy to collaborate with Oncotest, a pioneer
and a leader in the area, and we are looking forward to extending our partnership even
further towards the achievement of personalized medicine.”

About Oncotest

Oncotest is a CRO dedicated to the preclinical profiling of novel anti-cancer
molecules, facilitating the optimal planning of clinical trials. Promising indications,
novel combinations of anti-cancer molecules and potential biomarkers are identified using
a combination of in vitro and in vivo tests with Oncotest’s extensively characterized
collection of more than 400 unique patient-derived tumor xenografts (PDX) propagated in
nude mice. PDX are known to replicate patient tumor responses to anti-cancer drugs to a
high degree. Ex vivo 3D assays are an important component of Oncotest’s assay portfolio
and standard panels of up to 200 PDX are offered for 3D assay campaigns. Clients benefit
from Oncotest’s industry leading experience. Oncotest, based in Freiburg, Germany, was
founded in 1993 by Prof. Heiner Fiebig, a clinical oncologist who pioneered the use of PDX
for anti-cancer drug discovery and development. The company is focused on preclinical
pharmacology of anti-cancer agents and works with large pharmaceutical and biotech
companies. http://www.oncotest.de

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of
companies with a focus on the development of prescription drugs that target unmet medical
needs. The group in-licenses, develops and/or co-develops promising biological and small
molecule drug candidates having reached clinical development phases I, II or III, as well
as earlier stage candidates. It develops its products for global registration and maximum
commercial potential. The products are out-licensed to pharmaceutical partners for sales
and marketing. Debiopharm is also active in the field of companion diagnostics with a view
to progressing in the area of personalized medicine. Debiopharm independently funds the
worldwide development of all of its products while providing expertise in pre-clinical and
clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group(TM), please visit:

http://www.debiopharm.com.

        Debiopharm S.A. Contact
        Beatrice Hirt
        Communication Coordinator
        bhirt@debiopharm.com
        Tel.: +41-21-321-01-11

        Additional Media Contacts
        In London
        Maitland
        Brian Hudspith
        Tel.: +44(0)20-7379-5151
        bhudspith@maitland.co.uk

        In New York
        Russo Partners, LLC
        Martina Schwarzkopf, Ph.D.
        Account Executive
        Tel.: +1-212-845-4292
        Fax: +1-212-845-4260
        martina.schwarzkopf@russopartnersllc.com

        Oncotest GmbH Contact
        Dr. Ingmar Peitz
        Business Development
        Ingmar.Peitz@Oncotest.de
        Tel.: +49(0)761-51559-42

SOURCE The Debiopharm Group


Source: PR Newswire